#60. Cracking the "Undruggable" Target

from Drug Discovery AI Talk · host Dr. Jake Chen

Welcome to today's episode, where we dive into a monumental breakthrough in oncology, i.e., cracking the "undruggable" KRAS mutation. For decades, pancreatic cancer has been notoriously lethal, with few treatment options. Enter daraxonrasib (RMC-6236), a revolutionary "molecular glue" that targets the active "ON" state of mutated RAS proteins. In the recent Phase 3 RASolute 302 trial, this targeted therapy nearly doubled overall survival for metastatic pancreatic cancer patients compared to standard chemotherapy, extending it to 13.2 months. Join us as we explore the structural biology behind this tri-complex inhibitor, its unique resistance profile, and the future of precision cancer therapy. Produced by Dr. Jake Chen.

Episode metadata supplied by the publisher feed · Published Jun 6, 2026

Embed this episode

Attribution link and audio player

NOW PLAYING

#60. Cracking the "Undruggable" Target

0:00 21:28

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Drug Discovery AI Talk?

This episode is 21 minutes long.

When was this Drug Discovery AI Talk episode published?

This episode was published on June 6, 2026.

Can I download this Drug Discovery AI Talk episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!